No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PGNY240621P30000
- 1.77
- -3.39-65.70%
15min DelayClose Jun 12 15:59 ET
1.77High1.77Low
1.77Open5.16Pre Close1 Volume178 Open Interest30.00Strike Price177.00Turnover88.91%IV-1.84%PremiumJun 21, 2024Expiry Date2.28Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6913Delta0.0929Gamma9.40Leverage Ratio-0.0756Theta-0.0046Rho-6.50Eff Leverage0.0151Vega
Intraday
- 5D
- 1D
News
Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth
Express News | Progyny Outlook FY Revenue USD 225-250 Million
Progyny, Inc. to Present at Jefferies Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive
Progyny's (NASDAQ:PGNY) Performance Is Even Better Than Its Earnings Suggest
Investors were underwhelmed by the solid earnings posted by Progyny, Inc. (NASDAQ:PGNY) recently. We did some digging and actually think they are being unnecessarily pessimistic. NasdaqGS:PGNY Ear
Progyny:Bd of Directors Approved Shr Repurchase Up to $100M of Common Stk, Follows Program Announced Feb 29 >PGNY
Progyny:Bd of Directors Approved Shr Repurchase Up to $100M of Common Stk, Follows Program Announced Feb 29 >PGNY
Express News | Progyny Announces $100M Share Repurchase Program Approved By Board Of Directors; To Be Funded Through Available Cash Balances
Comments
Progyny's CEO, Pete Anevski, is thrilled about the executive team expansion, confident that the new members' expertise will boost the company's growth in fertility, family building, and women's health benefits. Both Higgins and Leist are excited to contribute to Progyny's growth and innovation.
Press Release: Progyny Expands Its Leadership TeamInvestors may be justifying Progyny's high P/E ratio by betting on its potential to outperform market growth. The company's strong forecast growth is believed to be upholding its high P/E and providing strong support to its share price.
Progyny, with a low ROCE score of 9.2%, underscores promising fundamentals following its foray into profitability. Having offered a notable 27% to shareholders over three years, its developing factors necessitate a deeper analysis for future investment opportunities.
$Progyny(PGNY.US$ Bought in at 64.40 and now what do I do sigh
6
3
$Costco(COST.US$ Costco (COST) target raised by Citigroup from $460 to $495 at Neutral. Stock currently around $448
$Etsy Inc(ETSY.US$ Etsy (ETSY) target raised by Loop Capital from $220 to $245 at Buy. Stock currently around $211
$Generac(GNRC.US$ Generac (GNRC) target raised by Roth Capital from $480 to $500 at Buy. Stock currently around $425
$Fortinet(FTNT.US$ Fortinet (FTNT) target raised by Cowen from $335 to $385 at Outperform. Stock currently around $288
$NVIDIA(NVDA.US$ NVIDIA (NVDA) target raised by Susquehanna from $220 to $250 at Positive. Stock currently around $206
$Progyny(PGNY.US$ Progyny (PGNY) target raiosed by Barclays from $72 to $80 at Overweight. Stock currently around $56
$Etsy Inc(ETSY.US$ Etsy (ETSY) target raised by Loop Capital from $220 to $245 at Buy. Stock currently around $211
$Generac(GNRC.US$ Generac (GNRC) target raised by Roth Capital from $480 to $500 at Buy. Stock currently around $425
$Fortinet(FTNT.US$ Fortinet (FTNT) target raised by Cowen from $335 to $385 at Outperform. Stock currently around $288
$NVIDIA(NVDA.US$ NVIDIA (NVDA) target raised by Susquehanna from $220 to $250 at Positive. Stock currently around $206
$Progyny(PGNY.US$ Progyny (PGNY) target raiosed by Barclays from $72 to $80 at Overweight. Stock currently around $56
3
Read more